{"id":"NCT02057250","sponsor":"Sanofi","briefTitle":"To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis","officialTitle":"A Multicenter, Randomized, Open-Label, Parallel-Group Usability Study Of The Sarilumab Auto-Injector Device And A Prefilled Syringe In Patients With Moderate To Severe Active Rheumatoid Arthritis Who Are Candidates For Anti-IL6R Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03","primaryCompletion":"2015-02","completion":"2016-03","firstPosted":"2014-02-07","resultsPosted":"2017-06-20","lastUpdate":"2017-06-20"},"enrollment":217,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["RA"],"interventions":[{"type":"DRUG","name":"Sarilumab","otherNames":["SAR153191","REGN88"]},{"type":"DEVICE","name":"Auto-Injector Device (AID)","otherNames":[]},{"type":"DEVICE","name":"Pre-filled Syringe (PFS)","otherNames":[]},{"type":"DRUG","name":"Methotrexate","otherNames":[]},{"type":"DRUG","name":"Sulfasalazine","otherNames":[]},{"type":"DRUG","name":"Leflunomide","otherNames":[]},{"type":"DRUG","name":"Hydroxychloroquine","otherNames":[]}],"arms":[{"label":"Sarilumab 150 mg by AID","type":"EXPERIMENTAL"},{"label":"Sarilumab 150 mg by PFS","type":"EXPERIMENTAL"},{"label":"Sarilumab 200 mg by AID","type":"EXPERIMENTAL"},{"label":"Sarilumab 200 mg by PFS","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo collect real-use data of the sarilumab auto-injector device (AID) used by rheumatoid arthritis (RA) participants.\n\nSecondary Objective:\n\nTo compare the pharmacokinetic (PK) exposure of sarilumab administered by AID versus prefilled syringes (PFS).","primaryOutcome":{"measure":"Number of Validated AID Associated Product Technical Failures (PTFs)","timeFrame":"Baseline up to Week 12","effectByArm":[{"arm":"Sarilumab 150 mg by AID (AID Assessment Phase)","deltaMin":0,"sd":null},{"arm":"Sarilumab 200 mg by AID (AID Assessment Phase)","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":53,"countries":["United States","Chile","Mexico","Poland","Russia","South Africa"]},"refs":{"pmids":["29209946"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":56},"commonTop":["Neutropenia","Upper respiratory tract infection","Injection site erythema","Urinary tract infection","Sinusitis"]}}